Nitrosamine impurities are a class of chemical compounds, some of which are potentially carcinogenic, that can form or be introduced in drug substances or products during manufacturing, storage, or through reactions with excipients and packaging components. In pharmaceutical quality documentation and regulatory submissions, they are addressed through risk assessments, validated analytical methods, and specified control limits that must be justified with stability and release data.
Nitrosamine impurity content appears in drug substance specifications, analytical method validation reports, risk assessment narratives, stability study summaries, and deficiency responses. In eCTD Module 3 quality sections, translators must keep compound names, limits, and units precise, and preserve the difference between acceptable intake and measured levels while adapting regulatory terms to the target market.
A common error is mixing up specific nitrosamine names or translating “acceptable intake” with vague wording that loses the numeric limit. Another mistake is omitting units such as ng/day or converting them incorrectly, which can make a control limit appear far stricter or looser than intended during regulatory quality review.
FDA, CE/MDR and NMPA reviewers assess the submitted wording itself. Regulatory bodies require traceable, accountable translation, and an inconsistent term can delay or fail a submission.
Angel Translation locks terms like this into a project terminology base before expert review begins, so the same source term resolves to the same target term across every document in a submission — and stays consistent in the next revision. See the 8-step AI + expert workflow.
Send us the files. Acknowledged in 4 hours, quoted in 24.
Request a Quote →Life Science solutions →